{
    "nctId": "NCT00362973",
    "briefTitle": "PET Scans in Assessing Response To Treatment in Patients Receiving Hormone Therapy or Trastuzumab for Breast Cancer",
    "officialTitle": "Early Assessment of Response to Targeted Breast Cancer Therapy",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 42,
    "primaryOutcomeMeasure": "Percent change in fludeoxyglucose F 18-positron emission tomography (FDG-PET) standardized uptake value and change in markers of proliferation (Ki67) at 2 weeks",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Newly diagnosed breast cancer with 1 of the following:\n\n  * Hormone receptor-positive disease and planning to receive treatment with neoadjuvant aromatase inhibitor and ovarian suppression therapy (if premenopausal)\n  * Recurrent and/or metastatic hormone receptor-positive disease and planning to receive treatment with an aromatase inhibitor and ovarian suppression therapy (if premenopausal)\n  * Metastatic HER-2/neu-positive disease and planning to receive treatment with neoadjuvant trastuzumab (Herceptin\u00ae)\n  * Recurrent HER-2/neu-positive disease and planning to receive treatment with trastuzumab (Herceptin\u00ae)\n* Tumor must be accessible for biopsy and assessable for response\n\n  * Tissue block must be available for review of experimental markers or patient must be willing to undergo biopsy\n* Evaluable disease by FDG-PET scan\n* Available for positron emission tomography (PET) imaging with a clinical indication for PET scan\n\n  * May aslo be enrolled on an experimental nuclear imaging study of 16\u03b1-fluoroestradiol F 18-PET scan (if hormone positive)\n* Concurrently receiving treatment (hormonal or other) for breast cancer\n* Hormone receptor status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\n* Female or male\n* Postmenopausal or premenopausal\n* Life expectancy \u2265 2 months\n* No uncontrolled diabetes mellitus or other comorbidity that would preclude imaging\n* Not pregnant\n* Negative pregnancy test\n* Able to tolerate scanning (e.g., no claustrophobia or severe pain)\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* Concurrent participation on another clinical study or other imaging studies allowed",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}